AURELIA ONLINE
AURELIA ONLINE
GLP-1 MEDICAL WEIGHT CARE
Mounjaro and Birth Control / Mounjaro / Medical weight care

Mounjaro and Birth Control: Oral Contraceptive Absorption and Backup Contraception

It is okay to ask before deciding on your own.

Side effects, dose changes, pregnancy/contraception, surgery, severe abdominal pain, or poor intake may require individualized medical review.

Mounjaro and Birth Control: Oral Contraceptive Absorption and Backup ContraceptionAURELIA ONLINEChiaroクリニックSelf-pay care

A guide to Mounjaro and contraception: delayed gastric emptying, reduced oral contraceptive exposure, backup contraception after initiation or dose escalation, and pregnancy planning.

※This article is for general education. Diagnosis, prescription, dose adjustment, stopping, or restarting treatment must be decided by a physician.

Contents
How to use this article

This article organizes a common patient concern using product information, clinical literature, and practical consultation points.

Check first

Seek advice early if symptoms are severe, dehydration is possible, pregnancy is possible, surgery is planned, or other medicines are used.

Conclusion: users of oral contraceptives should review backup contraception at initiation and escalation

Tirzepatide delays gastric emptying and may affect absorption of oral medicines. The US label recommends switching to a non-oral method or adding barrier contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.

ItemApproximate numberHow to interpret
EE AUC約20%低下チルゼパチド5mg単回投与試験として紹介。
開始後4週間米国添付文書のバックアップ避妊期間。
各増量後4週間経口避妊薬使用者で確認。
Risk/attention level image
60EE AUC ↓20%80Start 4 weeks80Escalation 4w30Non-oral

Numbers from oral contraceptive interaction data

A review describes approximately 20% lower ethinyl estradiol AUC after a single 5 mg tirzepatide dose with an oral contraceptive.

Numbers vary by patient background, trial design, dose, and concomitant medicines. Your risk should be interpreted using symptoms, dose, history, and other medicines.

Common misunderstanding

When symptoms appear, some patients immediately assume the medicine is unsuitable, while others try to tolerate everything because the symptoms are common. Both reactions can be unsafe. It is better to separate mild discomfort from symptoms that interfere with daily life, dehydration, low glucose, pregnancy-related concerns, or abdominal emergencies.

Notes that help consultation

Clinicians can judge more accurately when they know the last injection date, current dose, treatment week, recent escalation, food intake, fluid intake, bowel movements, weight change, exercise, alcohol, medical history, and other medicines. Insulin, sulfonylureas, diuretics, blood pressure medicines, oral contraceptives, and anticoagulants can change the interpretation.

Lifestyle adjustment

The goal is not simply to eat as little as possible. Even with reduced appetite, patients need protein, fluids, tolerable carbohydrates, bowel regularity, sleep, and safe movement. When symptoms appear, safety and continuation are more important than faster weight loss.

When to seek advice

Mild symptoms with good fluid intake and normal daily function may improve with meal and hydration adjustments. Severe pain, repeated vomiting, fever, confusion, dehydration, pregnancy possibility, upcoming surgery, or a desire to change dose should prompt medical review.

FAQ

Q. Can I decide based only on this article?

No. This is general information. Strong symptoms, pregnancy, surgery, medicines, hypoglycemia, or abdominal pain require medical review.

Q. Can I reduce or skip the dose myself?

Avoid changing the dose on your own. If side effects occur, discuss delay, dose reduction, or restart with a physician.

Q. Can I ask via LINE before booking?

Yes. You can ask via LINE before booking.

Related pages

References

  1. Eli Lilly and Company. MOUNJARO US Prescribing Information / Medication Guide.
  2. European Medicines Agency. Mounjaro EPAR Product Information.
  3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
  4. Kindel TL, et al. Multi-society clinical practice guidance for safe perioperative use of GLP-1 receptor agonists. 2024.
  5. Skelley JW, et al. Impact of tirzepatide and GLP-1 receptor agonists on oral hormonal contraception. 2024.

Numbers are general information based on trials and product information. Individual risk and action should be determined in consultation.

Need to apply this to your situation?

You can discuss symptoms, dose, weight change, intake, other medicines, and a safe continuation plan.

Mounjaro consultationCheck side effects, dose, and continuation online
Book